Efficacy of oral chlorhexidine in critical care by Wise, Matt P et al.
Page 1 of 1
(page number not for citation purposes)
Available online http://ccforum.com/content/12/3/419
In their review of airway hygiene, Jelic and colleagues
highlighted that colonization or infection of the upper airway
precedes the development of ventilator-associated pneu-
monia [1]. Although the effects of chlorhexidine on reducing
pneumonia were discussed, there was no mention of the
possible contribution of physical plaque removal, in particular
tooth brushing, which is often performed either infrequently or
inadequately in mechanically ventilated patients [1]. Such
removal is important because in critically ill patients the
normal microflora of dental plaque becomes rapidly colonized
by potential pathogens, and this biofilm serves as a reservoir
for the subsequent development of ventilator-associated
pneumonia [2,3].
Physical removal of dental plaque is essential for the optimal
benefit of chlorhexidine since its primary action is inhibition of
plaque formation. Whilst chlorhexidine kills both Gram-
negative bacteria and Gram-positive bacteria by damaging
their cell wall, its antiplaque activity is superior to other
antiseptics with greater antibacterial activity. This superior
activity occurs because chlorhexidine is absorbed onto oral
surfaces and is released over a long period of time. This
property, known as substantivity, explains why chlorhexidine
is excellent at inhibiting plaque formation in a clean mouth but
is otherwise of limited efficacy [4]. It is also not generally
appreciated that if toothpaste is used prior to chlorhexidine
then it must be thoroughly removed to prevent formation of
inactive low-solubility salts [5].
Oral chlorhexidine is widely used in critical care practice and
has been the subject of many investigations in mechanically
ventilated patients. These studies unfortunately do not
address the essential need for mechanical cleaning prior to
chlorhexidine use and therefore potentially underestimate the
benefit of this agent in reducing ventilator-associated
pneumonia.
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Authors’ response
Sanja Jelic, Jennifer A Cunningham and Phillip Factor
We appreciate the interest of Wise and colleagues in our
recent paper and agree with their helpful comments. We did
not mention the possible contribution of physical dental plaque
removal to reducing the incidence of nosocomial pneumonia
because no randomized trials addressing this question are
available at present. We agree with Wise and colleagues that
studies assessing the effects of mechanical cleaning prior to
chlorhexidine application are needed to better define the
benefit of this agent in reducing the incidence of nosocomial
pneumonia in the intensive care unit.
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